The countries with the highest prevalence of multiple sclerosis include Canada, San Marino, Denmark, and Sweden. Multiple sclerosis (MS) is a disease that affects communication in parts of the nervous system and damages the brain and spinal cord. Some of those with MS eventually become disabled due to the disease, but many can still walk, if not with the aid of a cane or crutches.

Symptoms

Symptoms of MS frequently affect movement, and can cause vision problems, slurred speech, fatigue, and trouble with coordination. Symptoms can vary greatly from person to person and people with MS may experience periods where symptoms improve partially or completely and then relapse. The most common symptoms that keep those with MS from working include fatigue, difficulty walking, standing and moving around, weakness, and cognitive impairment.

Impact of MS

Multiple sclerosis can impact the lives of those living with the disease in many ways. A survey from 2018 of people suffering from MS found that 24 percent stated they had chosen to stop working due to the disease, while 13 percent lost their job and 12 percent had to take medical leave. MS can also impact the personal and intimate lives of those who suffer. The same survey found 38 percent of respondents said fatigue from MS negatively impacted their sex life.

This dataset present information on the age-sex specific incidence rate of multiple sclerosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

AbstractObjective: To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets. Methods: A validated algorithm was applied to private, military, and public AHC datasets to identify adult cases of MS between 2008 and 2010. In each dataset, we determined the 3-year cumulative prevalence overall and stratified by age, sex, and census region. We applied insurance-specific and stratum-specific estimates to the 2010 US Census data and pooled the findings to calculate the 2010 prevalence of MS in the United States cumulated over 3 years. We also estimated the 2010 prevalence cumulated over 10 years using 2 models and extrapolated our estimate to 2017. Results: The estimated 2010 prevalence of MS in the US adult population cumulated over 10 years was 309.2 per 100,000 (95% confidence interval [CI] 308.1–310.1), representing 727,344 cases. During the same time period, the MS prevalence was 450.1 per 100,000 (95% CI 448.1–451.6) for women and 159.7 (95% CI 158.7–160.6) for men (female:male ratio 2.8). The estimated 2010 prevalence of MS was highest in the 55- to 64-year age group. A US north-south decreasing prevalence gradient was identified. The estimated MS prevalence is also presented for 2017. Conclusion: The estimated US national MS prevalence for 2010 is the highest reported to date and provides evidence that the north-south gradient persists. Our rigorous algorithm-based approach to estimating prevalence is efficient and has the potential to be used for other chronic neurologic conditions. Usage notesPrev of MS in the US-E-Appendix-Feb-19-2018

This statistic shows the number of individuals with multiple sclerosis in the United Kingdom in 2014, by country. In this year, over 107.7 thousand individuals in the United Kingdom had multiple sclerosis.

This statistic displays the distribution of inpatient multiple sclerosis cases in the United States by selected demographic group in 2012. In that year, 35.5 percent of multiple sclerosis inpatient cases were male.

BackgroundPrevious genetic and epidemiological studies have examined subpopulations from the Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis (CCPGSMS) patient cohort, but an encompassing analysis of the study population has not yet been carried out.ObjectiveThis retrospective study examines patterns of multiple sclerosis (MS) prevalence in 13,663 cohort members, including 4,821 persons with MS or suspected MS and 8,842 family members.MethodsWe grouped participants into epidemiologic subgroups based on age of MS onset, clinical stage at diagnosis, symptom type at disease onset, sex, proband status, disability as measured by the EDSS, and ancestry based on reported ethnicity.ResultsWe observed a 2.7:1 MS prevalence ratio of women to men, though disease severity was greater for male patients. Variation in the age of disease onset between patients was only slightly associated with sex and strongly associated with disease type. Specific types of clinical symptoms at disease onset were associated with the prognosis. Regional residence did not correlate with disease onset, type, or severity.ConclusionPopulation trends, as presented here, are not explained by environmental factors alone, highlighting the need for a comprehensive genetic analysis to understand disease variance across families.

This dataset present information on the age-standardized incidence rate of multiple sclerosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

In the fiscal year 2021-2022, around 0.3 percent of adults aged 20 years and older in Canada suffered from multiple sclerosis. At that time, the prevalence of multiple sclerosis was highest in Nova Scotia. This statistic illustrates the prevalence of multiple sclerosis among adults 20 years and older in Canada in 2021-2022, by province and territory.

BackgroundMultiple sclerosis (MS) is a progressively debilitating disorder that has seen a notable rise in prevalence in recent years. This study examines the burden of MS from 1990 to 2019, providing a detailed analysis by age, sex, and sociodemographic index (SDI) across 204 countries and territories.MethodsData on the prevalence, death and disability-adjusted life years (DALYs) attributable to MS were obtained from the publically available Global Burden of Disease 2019 project. The estimates are reported as numbers, percentages, and age-standardized rates per 100,000, accompanied by 95% uncertainty intervals.ResultsIn 2019, MS accounted for 1.8 million prevalent cases, 22.4 thousand deaths and 1.2 million DALYs worldwide. There were significant declines in the global age-standardized prevalence, mortality and DALY rates of MS over the period 1990–2019. In 2019, females exhibited a higher global point prevalence and a greater total number of prevalent MS cases than males across all age groups. At the regional level, a non-linear relationship was observed between the age-standardized DALY rate of MS and SDI.ConclusionAlthough the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. Integrating MS and its associated risk factors into healthcare planning is vital, especially in areas with high levels of socioeconomic development.

Introduction/objectivesMultiple sclerosis (MS) leads to physical and cognitive disability, which in turn impacts the socioeconomic status of the individual. The altered socioeconomic trajectory combined with the critical role of aging in MS progression could potentially lead to pronounced differences between MS patients and the general population. Few nations have the ability to connect long-term clinical and socioeconomic data at the individual level, and Denmark's robust population-based registries offer unique insights. This study aimed to examine the socioeconomic aspects of elderly Danish MS patients in comparison to matched controls from the general population.MethodsA nationwide population-based study in Denmark was conducted, comprising all living MS patients aged 50 years or older as of 1 January 2021. Patients were matched 1:10 based on sex, age, ethnicity, and residence with a 25% sample of the total Danish population. Demographic and clinical information was sourced from the Danish Multiple Sclerosis Registry, while socioeconomic data were derived from national population-based registries containing details on education, employment, social services, and household characteristics. Univariate comparisons between MS patients and matched controls were then carried out.ResultsThe study included 8,215 MS patients and 82,150 matched individuals, with a mean age of 63.4 years (SD: 8.9) and a 2:1 female-to-male ratio. For those aged 50–64 years, MS patients demonstrated lower educational attainment (high education: 28.3 vs. 34.4%, P < 0.001) and fewer received income from employment (46.0 vs. 78.9%, P < 0.001), and working individuals had a lower annual income (48,500 vs. 53,500€, P < 0.001) in comparison to the controls. Additionally, MS patients within this age group were more likely to receive publicly funded practical assistance (14.3 vs. 1.6%, P < 0.001) and personal care (10.5 vs. 0.8%, P < 0.001). Across the entire population, MS patients were more likely to live alone (38.7 vs. 33.8%, P < 0.001) and less likely to have one or more children (84.2 vs. 87.0%, P < 0.001).ConclusionMS presents significant socioeconomic challenges among the elderly population, such as unemployment, reduced income, and increased dependence on social care. These findings underscore the pervasive impact of MS on an individual's life course, extending beyond the clinical symptoms of cognitive and physical impairment.

Systetmatic review and meta-analysis on the prevalence of obesity in patients with multiple sclerosis

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. The course of MS seems to be unpredictable as some people diagnosed with the condition appear to be normal and healthy for a few years after diagnosis, while others may be debilitated very quickly after diagnosis. People with MS experience a host of symptoms, which may vary with the course of the disease. The estimated prevalence and incidence of MS vary greatly between countries, within countries, and by age and sex. Read More

This statistic displays the rate of multiple sclerosis (MS) in the United States separated by the 37th parallel into a northern part and a southern part, as of 2015. It is estimated that there are between 110 to 140 cases of MS per 100,000 people in the Northern States. MS rates in the northern part of the country are twice as high as in the southern parts of the United States. There are about 200 new cases that are diagnosed every week in the country. MS is a disease that damages nerve cells in the brain and spinal cord which disrupts the ability of the nervous system to communicate with the body.

This statistic shows the number of individuals with multiple sclerosis in the United Kingdom in 2014, by age and gender. In 2014 over 22 thousand women aged between 50 and 59 years had multiple sclerosis.

aA–G were affiliated with the SMSreg only or both registers, and H and I were affiliated with the NPR only.bThe probability was 0 or 1 depending on whether the date of diagnosis in the SMSreg was from 2001 to 2008.cThe earliest date of diagnosis could not have occurred between 2001 and 2008 due to an earlier date in the NPR.dThe date of diagnosis in the SMSreg could be 2009 or 2010.eEstimated from E and F.NPR, Swedish National Patient Register; SMSreg, Swedish Multiple Sclerosis Registry; NA, not applicable.Disjoint subsets of MS patients with respect to the earliest date of MS diagnosis registered in the Swedish National Patient Register (NPR) and/or the Swedish Multiple Sclerosis Registry (SMSreg).

Prospective cohort study was conducted in Mexican mestizo patients newly diagnosed with CIS who presented at the National Institute of Neurology and Neurosurgery (NINN) in Mexico City, Mexico, between 2006 and 2010.

AbstractObjective: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. Methods: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. Results: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. Conclusions: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist., Usage notesNelson_SupplementalTable_E1Nelson_SupoplementalTable_E1.docx

P-values (crude) were calculated from analysis of variance (ANOVA), α = 0.05.P-values (crude) were calculated from chi-square analysis (Fischer exact test), α = 0.05.**P-values (crude) were calculated from Kruskal Wallis; α = 0.05.Missing observations#; n (number of missing values) ranging from 0–44.FSS: Fatigue Severity Scale; EDSS: Expanded Disability Status Scale; BDI: Beck Depression Inventory, RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS.

MS prevalence based on region, gender, provinces, year of study and design.

This item is part of the SAFEHR scheme at UCLH. The purpose of the scheme is to publicly display what kinds of patient data we use, to encourage collaboration and transparency. More information can be found at https://safehr-data.github.io/uclh-research-discovery/This dataset describes the structured health records used as part of the MS-PINPOINT project at UCL. It mainly describes the patient demographics such as patient reported gender, ethnicity and other features. Any category with less than 5 entries is not reported in line with privacy guidelines.